Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
1993-03-09
2011-11-22
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S069100, C435S069300, C530S300000
Reexamination Certificate
active
08062642
ABSTRACT:
The present invention is directed to a method of expressing the papillomavirus capsid protein coding sequence in a cell using an expression system under conditions facilitating expression of the protein in the cell.In another aspect of the invention, it has been discovered that virus-like particle(s) (VLPs), fragment(s), capsomer(s) or portion(s) thereof are formed from the papillomavirus capsid protein. It was further discovered that the virus-like particle(s) comprises antigenic characteristics similar to those of native infectious papillomavirus particles.In an embodiment of the invention, there is provided a method of expressing the L1 major capsid protein of human papillomavirus type-11 (HPV-11) in Sf-9 insect cells using the baculovirus expression system, and the production of HPV-11 virus-like particles.
REFERENCES:
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4870023 (1989-09-01), Fraser et al.
patent: 5041385 (1991-08-01), Kingsman et al.
patent: 5045447 (1991-09-01), Minson
patent: 5057411 (1991-10-01), Lancaster et al.
patent: 5071757 (1991-12-01), Kreider et al.
patent: 5169766 (1992-12-01), Schuster et al.
patent: 5346811 (1994-09-01), Galindo-Castrol
patent: 5437951 (1995-08-01), Lowy et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5744142 (1998-04-01), Lowy et al.
patent: 5871998 (1999-02-01), Lowy et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6013262 (2000-01-01), Frazer et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6261765 (2001-07-01), McCarthy et al.
patent: 6361778 (2002-03-01), Gissmann et al.
patent: 6599508 (2003-07-01), Gissmann et al.
patent: 6613557 (2003-09-01), Frazer et al.
patent: 7169585 (2007-01-01), Frazer et al.
patent: 7220419 (2007-05-01), Lowy et al.
patent: 7361356 (2008-04-01), Lowy et al.
patent: 7416732 (2008-08-01), Gissmann et al.
patent: 7476389 (2009-01-01), Frazer et al.
patent: 2009/0252761 (2009-10-01), Frazer et al.
patent: 0 343 783 (1989-04-01), None
patent: 0 390 252 (1990-03-01), None
patent: WO 94/00152 (1992-06-01), None
patent: WO 9210513 (1992-06-01), None
patent: WO 92/16636 (1992-10-01), None
patent: WO 9216636 (1992-10-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO9302184 (1993-02-01), None
patent: WO 94/05792 (1994-03-01), None
Ellis, R.W. “New technologies for making vaccines” In: Vaccines Plotkin and Mortimer Eds., W.B. Saunders Co. 1988, pp. 568-575.
Rose, R.C et al. J. Virology 67(4): 1936-1944 (1993).
Haginsec, M.E. et al. J. Virology 67(1): 315-322 (1993).
Xi, S.Z. et al. J. Gen. Virology 72: 2981-2988 (1991).
Zhou, J. et al. Virology 185: 251-257 (1991).
Browne, H et al. J. Gen. Virol 69: 1263-1273, 1988.
Kirnbauer et al. Journal of Virology 67:6929-6936, 1993.
Kirnbauer et al. Journal of the National Cancer Institute 86:494-499, 1994.
Kirnbauer, et al., Papillomavirus L1 major capsid protein self assemblies into virus-like particles that are highly immunogenic 1992,Proc. Natl. Acad. Sci. USA, vol. 89, pp. 12180-12184.
Karasuyama et al., “Establishment of Mouse Cell Lines Which Constitutively Secrete Large Quantities of Interleukin 2, 3, 4 or 5, Using Modified cDNA Expression Vectors,”Eur. J. Immunol., 18:97-104(1988).
Anisimová et al., “Presence and Type Specificity of Papillomavirus Antibodies Demonstrable by Immunoelectron Microscopy Tests in Samples from Patients with Warts,”J. Gen. Virol. 71:419-22 (1990).
Baker et al., “Structures of Bovine and Human Papillomaviruses,”Biophys. J. 60:1445-56 (1991).
Biberstein, “Immunization Therapy of Warts,”Arch. Dermatol. Syphilol. 50:12-22 (1944).
Bonnez et al., “Antibody Response to Human Papillomavirus (HPV) Type 11 in Children with Juvenile-Onset Recurrent Respiratory Papillomatosis (RRP),”Virology188:384-87 (1992).
Bonnez et al., “Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs,”J. Infect. Dis. 165:376-80 (1992).
Bonnez et al., “Evolution of the Antibody Response to Human Papillomavirus Type 11 (HPV-11) in Patients with Condyloma Acuminatum According to Treatment Response,”J. Med. Virol. 39:340-44 (1993).
Bonnez et al., “The PstI-XhoII Restriction Fragment of the HPV-6b L1 ORF Lacks Immunological Specificity as Determined by Sera from HPV6 Condyloma Acuminatum Patients and Controls,” in [Papillomaviruses] 124 UCLA Symposia on Molecular and Cellular Biology: New Series 77-80 (1990).
Bonnez et al., “Use of Human Papillomavirus Type 11 Virons in an ELISA to Detect Specific Antibodies in Humans with Condylomata Acuminata,”J. Gen. Virol. 72:1343-47 (1991).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-10 (1990).
Chan et al., “Phylogenetic Analysis of 48 Papillomavirus Types and 28 Subtypes and Variants: A Showcase for the Molecular Evolution of DNA Viruses,”J. Virol. 66(10):5714-25 (1992).
Christensen & Kreider, “Antibody-Mediated Neutralization in Vivo of Infectious Papillomaviruses,”J. Virol. 64(7):3151-56 (1990).
Christensen & Kreider, “Neutralization of CRPV Infectivity by Monoclonal Antibodies That Identify Conformational Epitopes on Intact Virions,”Virus Res. 21:169-79 (1991).
Christensen et al., “Detection of Human Serum Antibodies That Neutralize Infectious Human Papillomavirus Type 11 Virions,”J. Gen. Virol. 73:1261-67 (1992).
Christensen et al., “Monoclonal Antibody-Mediated Neutralization of Infectious Human Papillomavirus Type 11,”J. Virol. 64(11):5678-81 (1990).
Cole & Danos, “Nucleotide Sequence and Comparative Analysis of the Human Papillomavirus Type 18 Genome: Phylogeny of Papillomaviruses and Repeated Structure of the E6 and E7 Gene Products,”J. Mol. Biol. 193:599-608 (1987).
Cole & Mango, “cis-Acting Determinants ofc-mycmRNA Stability,”Enzyme44:167-80 (1990).
Cornelissen et al., “Localization of Human Papillomavirus Type 16 DNA Using the Polymerase Chain Reaction in the Cervix Uteri of Women with Cervical Intraepithelial Neoplasia,”J. Gen. Virol. 70:2555-62 (1989).
Crum & Levine, “Human Papillomavirus Infection and Cervical Neoplasia: New Perspectives,”Int'l J. Gynecol. Pathol. 3:376-88 (1984).
Danos et al., “Papillomavirus Genomes: Sequences and Consequences,”J. Invest. Dermatol. 83(1 Supp.):7s-11s (1984).
Dartmann et al., “The Nucleotide Sequence and Genome Organization of Human Papilloma Virus Type 11,”Virology151:124-30 (1986).
Doorbar & Gallimore, “Identification of Proteins Encoded by the L1 and L2 Open Reading Frames of Human Papillomavirus 1a,”J. Virol. 61(9):2793-99 (1987).
Dürst et al., “A Papillomavrus DNA from a Cervical Carcinoma and Its Prevalence in Cancer Biopsy Samples from Different Geographic Regions,”Proc. Nat'l Acad. Sci. USA80:3812-15 (1983).
European Search Report, European Patent Application No. EP 05 07 5369 (Aug. 9, 2005).
Frazer, Slides Presented at the 10thInternational Papillomavirus Workshop (Seattle, Washington, Jul. 20-26, 1991).
Ghim et al., “Comparison of Neutralization of BPV-1 Infection of C127 Cells and Bovine Fetal Skin Xenografts,”Int'l J. Cancer49:285-89 (1991).
Ghim et al., “HPV-1 L1 Protein Expressed in cos Cells Displays Conformational Epitopes Found on Intact Virions,”Virology190:548-52 (1992).
Gissmann et al., “Human Papilloma Viruses (HPV): Characterization of Four Different Isolates,”Virology76:569-80 (1977).
Gissmann et al., “Human Papillomaviruses and Cervical Cancer,”Cancer Cells5:275-80 (1987).
Hood et al., “Clarification and Retraction: Immunology,”Proc. Nat'l Acad. Sci. USA88:6899 (1991).
Howley, “Papillomavirinae and Their Replication,” in 2 Fundamental Virology 743-68 (Bernard N. Fields and David M. Knipe eds., 2d ed. 1991).
International
Bonnez William
Reichman Richard
Rose Robert
Goldman Michael L.
LeClairRyan, a Professional Corporation
Peng Bo
University of Rochester
LandOfFree
Production of papillomavirus capsid protein and virus-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of papillomavirus capsid protein and virus-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of papillomavirus capsid protein and virus-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298267